NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Crash,

I think you are wrong. DCVax-L is not explicitly mentioned. But no other DC vaccines can be pulsed with tumor lysate like DCVax-L did. In this case, without doubt, it is the NWBO technology that can let DCs digest tumor lysate and present tumor-associated antigens from three types of cold tumors to immune system. If it were not DCVax-L, BPs would have bought whoever has the technology and bankrupted our company.

BTW, CYT107 is owned by RevImmune.